Obstructive Hypertrophic Cardiomyopathy

The introduction of mavacamten represents a major shift in the treatment of obstructive hypertrophic cardiomyopathy, but raises dosing and drug-drug interaction challenges.

Improvements in exercise capacity and quality of life associated with aficamten coincided with significant cardiac remodeling and replacement fibrosis in patients with obstructive hypertrophic cardiomyopathy, a speaker reported.

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten improved exercise capacity and quality of life compared with placebo, according to the results of the SEQUOIA-HCM trial.

Dysmenorrhea and polycystic ovary syndrome are linked to a long-term increased risk for CVD in women, according to a presentation at the American Heart Association Scientific Sessions.

Compared with placebo, aficamten was associated with increased exercise capacity and improvements in symptoms of obstructive hypertrophic cardiomyopathy, according to topline results of the phase 3 SEQUOIA-HCM trial.

Bristol Myers Squibb announced that the FDA has approved updated labeling for mavacamten to reflect positive data from the VALOR-HCM trial.

The FDA has issued a complete response letter to Cytokinetics for omecamtiv mecarbil, an investigational, selective small molecule cardiac myosin activator for treatment of HF with reduced ejection fraction, according to a press release.

Mavacamten improved a range of cardiopulmonary exercise testing parameters beyond peak oxygen uptake in patients with obstructive hypertrophic cardiomyopathy in the EXPLORER-HCM randomized trial, researchers reported.

In patients with obstructive hypertrophic cardiomyopathy, septal reduction therapy was associated with reduced risk for HF readmissions, researchers reported in the Journal of the American College of Cardiology.